In the BioHarmony Drug Report Database
Bivalirudin
Angiomax, Angiomax Rtu, Bivalirudin (bivalirudin) is a protein pharmaceutical. Bivalirudin was first approved as Angiomax on 2000-12-15. It is used to treat unstable angina in the USA. The pharmaceutical is active against prothrombin. Angiomax’s patent is valid until 2028-07-27 (FDA).
Trade Name
|
Angiomax, Angiomax Rtu, Bivalirudin |
|---|---|
Common Name
|
bivalirudin |
ChEMBL ID
|
CHEMBL2103749 |
Indication
|
unstable angina |
Drug Class
|
Anticoagulants (hirudin type) |
Image (chem structure or protein)